Study indicates interleukin-6-dependant pathway dysregulation as a key druggable feature of COVID-19
In a recent study on the medRxiv* preprint server, researchers identified an interleukin 6 (IL-6) dependent alternative pathway as a therapeutic strategy against coronavirus disease 2019 (COVID-19).
AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results